ATE516017T1 - Feste pharmazeutische dosierform enthaltende ritonavir - Google Patents
Feste pharmazeutische dosierform enthaltende ritonavirInfo
- Publication number
- ATE516017T1 ATE516017T1 AT04816820T AT04816820T ATE516017T1 AT E516017 T1 ATE516017 T1 AT E516017T1 AT 04816820 T AT04816820 T AT 04816820T AT 04816820 T AT04816820 T AT 04816820T AT E516017 T1 ATE516017 T1 AT E516017T1
- Authority
- AT
- Austria
- Prior art keywords
- dosage form
- pharmaceutical dosage
- solid pharmaceutical
- form containing
- containing ritonavir
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 title 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 title 1
- 229960000311 ritonavir Drugs 0.000 title 1
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/650,178 US20050048112A1 (en) | 2003-08-28 | 2003-08-28 | Solid pharmaceutical dosage form |
| PCT/US2004/027401 WO2005039551A2 (en) | 2003-08-28 | 2004-08-23 | Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516017T1 true ATE516017T1 (de) | 2011-07-15 |
Family
ID=34217089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04816820T ATE516017T1 (de) | 2003-08-28 | 2004-08-23 | Feste pharmazeutische dosierform enthaltende ritonavir |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20050048112A1 (de) |
| EP (6) | EP2258344B1 (de) |
| JP (6) | JP4815348B2 (de) |
| KR (5) | KR101132602B1 (de) |
| CN (5) | CN102764244A (de) |
| AT (1) | ATE516017T1 (de) |
| AU (3) | AU2004283087C1 (de) |
| CA (2) | CA2536638C (de) |
| CR (3) | CR8256A (de) |
| CY (5) | CY1111981T1 (de) |
| DK (5) | DK2258345T3 (de) |
| EA (4) | EA020992B1 (de) |
| EC (1) | ECSP066397A (de) |
| ES (5) | ES2608720T3 (de) |
| HK (1) | HK1257502A1 (de) |
| HR (1) | HRP20110555T1 (de) |
| HU (3) | HUE031153T2 (de) |
| IL (3) | IL173939A (de) |
| ME (2) | ME00130B (de) |
| MX (2) | MXPA06002346A (de) |
| NO (3) | NO330282B1 (de) |
| NZ (2) | NZ579622A (de) |
| PL (5) | PL1663183T3 (de) |
| PT (5) | PT2258344E (de) |
| RS (2) | RS57663B1 (de) |
| SG (3) | SG179401A1 (de) |
| SI (5) | SI1663183T1 (de) |
| TW (1) | TWI342221B (de) |
| UA (1) | UA85564C2 (de) |
| WO (1) | WO2005039551A2 (de) |
| ZA (3) | ZA200801362B (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| ATE329579T1 (de) * | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| AU2012202831B2 (en) * | 2005-02-23 | 2015-01-22 | Abbvie Inc. | A solid pharmaceutical dosage formulation |
| KR20070025070A (ko) * | 2005-08-31 | 2007-03-08 | 주식회사 대웅제약 | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 |
| JP5231242B2 (ja) * | 2005-12-14 | 2013-07-10 | シプラ・リミテッド | ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ |
| DE602006017257D1 (de) * | 2005-12-14 | 2010-11-11 | Hoffmann La Roche | Hcv-prodrug-formulierung |
| WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
| EP1832281A1 (de) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes |
| EP1880715A1 (de) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmazeutisch annehmbare lösungsvermittelnde Zusammensetzung und diese enthaltende pharmazeutische Darreichungsform |
| CL2007002331A1 (es) * | 2006-08-10 | 2008-04-18 | Cipla Ltd | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. |
| CA2669938C (en) * | 2006-11-15 | 2016-01-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| DK3150586T3 (da) | 2007-02-23 | 2020-02-17 | Gilead Sciences Inc | Modulatorer af farmakokinetiske egenskaber af terapeutika |
| PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
| TWI583405B (zh) * | 2008-02-28 | 2017-05-21 | 艾伯維有限公司 | 錠劑及其製備 |
| WO2009153654A1 (en) * | 2008-06-17 | 2009-12-23 | Aurobindo Pharma Limited | Solid dosage forms of antiretrovirals |
| AU2009300866B2 (en) * | 2008-10-07 | 2013-03-28 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
| US20120121722A1 (en) | 2008-12-18 | 2012-05-17 | Anup Avijit Choudhury | Atazanavir formulations |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| US20110034489A1 (en) | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
| WO2011013110A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Unit dosage forms of hiv protease inhibitors |
| SMT202200321T1 (it) | 2010-10-01 | 2022-09-14 | Modernatx Inc | Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US20140066468A1 (en) * | 2011-03-07 | 2014-03-06 | Bandi Parthasaradhi Reddy | Amorphous form of lopinavir and ritonavir mixture |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| WO2012164575A2 (en) | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
| US20140206717A1 (en) * | 2011-08-16 | 2014-07-24 | John Higgins | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
| EP2564832A1 (de) | 2011-08-29 | 2013-03-06 | Hexal AG | Feste Dosierungsformen von HIV-Proteaseinhibitoren |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| US20150111909A1 (en) * | 2012-03-07 | 2015-04-23 | Ratiopharm Gmbh | Dosage form comprising non-crystalline lopinavir and crystalline ritonavir |
| ES2587559T3 (es) | 2012-03-07 | 2016-10-25 | Ratiopharm Gmbh | Forma farmacéutica que comprende lopinavir y ritonavir |
| CN103655571B (zh) * | 2012-09-11 | 2016-04-20 | 上海星泰医药科技有限公司 | 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法 |
| US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
| EP2900219B1 (de) | 2012-09-27 | 2016-07-06 | Basf Se | Lagerstabile, staubfreie, homogene teilchenförmige formulierung mit mindestens einem wasserlöslichen vitamin-e-derivat und mindestens einem hydrophilen polymer |
| EP2911651B1 (de) | 2012-09-27 | 2016-06-22 | Basf Se | Lagerstabile, staubfreie, homogene teilchenförmige formulierung mit mindestens einem wasserlöslichen vitamin-e-derivat und mindestens einem hydrophilen polymer |
| US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
| RU2505286C1 (ru) | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
| RU2543322C1 (ru) * | 2013-09-19 | 2015-02-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
| RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
| RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
| US20190038754A1 (en) * | 2017-08-07 | 2019-02-07 | SE Tylose, USA, Inc. | Pharmaceutical composition in solid extruded form |
| US20190269662A1 (en) * | 2018-03-02 | 2019-09-05 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
| CN108186578A (zh) * | 2018-03-27 | 2018-06-22 | 聊城大学 | 一种利托那韦固体分散体的制备方法 |
| EP3569225A1 (de) | 2018-05-18 | 2019-11-20 | Pharmaceutical Oriented Services Ltd | Feste dispersion mit ritonavir |
| TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
| CN114146061B (zh) * | 2020-09-07 | 2023-06-30 | 歌礼生物科技（杭州）有限公司 | 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法 |
| WO2022120194A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| CN113318076B (zh) * | 2021-06-02 | 2022-09-23 | 聊城大学 | 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法 |
| CN114557967B (zh) * | 2022-03-17 | 2023-06-02 | 乐普制药科技有限公司 | 一种利托那韦固体分散体的制备方法 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5542206A (en) | 1994-10-11 | 1996-08-06 | Lisch; Albert | Lure and tackle stacking container |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| DE19841244A1 (de) * | 1998-09-09 | 2000-03-16 | Knoll Ag | Verfahren und Vorrichtung zum Herstellen von Tabletten |
| ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| DE19913606A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen |
| DE19913692A1 (de) * | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| JP4753511B2 (ja) | 1999-06-04 | 2011-08-24 | アボット・ラボラトリーズ | 改良された医薬製剤 |
| ATE329579T1 (de) * | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
| CA2390092C (en) | 1999-11-12 | 2009-07-14 | Abbott Laboratories | Solid dispersion pharmaceutical formulations |
| CA2448864C (en) | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| ES2305434T3 (es) * | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| DE10213242A1 (de) | 2002-03-25 | 2003-10-16 | Abbott Gmbh & Co Kg | Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren |
| DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| CA2669938C (en) | 2006-11-15 | 2016-01-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
-
2003
- 2003-08-28 US US10/650,178 patent/US20050048112A1/en not_active Abandoned
-
2004
- 2004-08-23 SG SG2012008959A patent/SG179401A1/en unknown
- 2004-08-23 PL PL04816820T patent/PL1663183T3/pl unknown
- 2004-08-23 UA UAA200603276A patent/UA85564C2/ru unknown
- 2004-08-23 ES ES10181264.2T patent/ES2608720T3/es not_active Expired - Lifetime
- 2004-08-23 KR KR1020067004057A patent/KR101132602B1/ko not_active Ceased
- 2004-08-23 DK DK10181264.2T patent/DK2258345T3/en active
- 2004-08-23 ZA ZA200801362A patent/ZA200801362B/en unknown
- 2004-08-23 PL PL10181264T patent/PL2258345T3/pl unknown
- 2004-08-23 CA CA2536638A patent/CA2536638C/en not_active Expired - Fee Related
- 2004-08-23 ES ES10181250T patent/ES2399810T3/es not_active Expired - Lifetime
- 2004-08-23 CA CA2689639A patent/CA2689639C/en not_active Expired - Fee Related
- 2004-08-23 CN CN2012102597395A patent/CN102764244A/zh active Pending
- 2004-08-23 HU HUE10181264A patent/HUE031153T2/en unknown
- 2004-08-23 CN CN201510531654.1A patent/CN105106104A/zh active Pending
- 2004-08-23 SG SG200805563-4A patent/SG145690A1/en unknown
- 2004-08-23 EA EA200900292A patent/EA020992B1/ru not_active IP Right Cessation
- 2004-08-23 RS YU20060140A patent/RS57663B1/sr unknown
- 2004-08-23 PT PT101812501T patent/PT2258344E/pt unknown
- 2004-08-23 DK DK10181268.3T patent/DK2258346T3/da active
- 2004-08-23 SI SI200431719T patent/SI1663183T1/sl unknown
- 2004-08-23 PL PL10181268T patent/PL2258346T3/pl unknown
- 2004-08-23 SI SI200432367A patent/SI2258345T1/sl unknown
- 2004-08-23 PT PT101812683T patent/PT2258346T/pt unknown
- 2004-08-23 SG SG10201507902UA patent/SG10201507902UA/en unknown
- 2004-08-23 PT PT04816820T patent/PT1663183E/pt unknown
- 2004-08-23 NZ NZ579622A patent/NZ579622A/en not_active IP Right Cessation
- 2004-08-23 SI SI200431996T patent/SI2258344T1/sl unknown
- 2004-08-23 ME MEP-2008-176A patent/ME00130B/me unknown
- 2004-08-23 HR HR20110555T patent/HRP20110555T1/hr unknown
- 2004-08-23 KR KR20157009392A patent/KR20150044031A/ko not_active Withdrawn
- 2004-08-23 ES ES04816820T patent/ES2367173T3/es not_active Expired - Lifetime
- 2004-08-23 HU HUE10181268A patent/HUE035985T2/hu unknown
- 2004-08-23 DK DK15169378.5T patent/DK2942051T3/en active
- 2004-08-23 EP EP10181250A patent/EP2258344B1/de not_active Revoked
- 2004-08-23 KR KR1020127011945A patent/KR101457967B1/ko not_active Ceased
- 2004-08-23 DK DK04816820.7T patent/DK1663183T3/da active
- 2004-08-23 EP EP10181268.3A patent/EP2258346B1/de not_active Revoked
- 2004-08-23 PL PL10181250T patent/PL2258344T3/pl unknown
- 2004-08-23 EA EA200600473A patent/EA011924B1/ru not_active IP Right Cessation
- 2004-08-23 EA EA201301045A patent/EA033224B1/ru not_active IP Right Cessation
- 2004-08-23 CN CN201210259721.5A patent/CN102772380B/zh not_active Ceased
- 2004-08-23 DK DK10181250.1T patent/DK2258344T3/da active
- 2004-08-23 SI SI200432412T patent/SI2258346T1/sl unknown
- 2004-08-23 KR KR1020117025014A patent/KR101281994B1/ko not_active Ceased
- 2004-08-23 WO PCT/US2004/027401 patent/WO2005039551A2/en not_active Ceased
- 2004-08-23 ES ES15169378.5T patent/ES2666390T3/es not_active Expired - Lifetime
- 2004-08-23 ES ES10181268.3T patent/ES2653762T3/es not_active Expired - Lifetime
- 2004-08-23 JP JP2006524782A patent/JP4815348B2/ja not_active Expired - Lifetime
- 2004-08-23 EP EP15169378.5A patent/EP2942051B1/de not_active Revoked
- 2004-08-23 PT PT101812642T patent/PT2258345T/pt unknown
- 2004-08-23 PT PT151693785T patent/PT2942051T/pt unknown
- 2004-08-23 MX MXPA06002346A patent/MXPA06002346A/es active IP Right Grant
- 2004-08-23 EP EP10181264.2A patent/EP2258345B1/de not_active Revoked
- 2004-08-23 AU AU2004283087A patent/AU2004283087C1/en not_active Revoked
- 2004-08-23 PL PL15169378T patent/PL2942051T3/pl unknown
- 2004-08-23 EA EA201890737A patent/EA201890737A3/ru unknown
- 2004-08-23 AT AT04816820T patent/ATE516017T1/de active
- 2004-08-23 EP EP17210362.4A patent/EP3354261A1/de not_active Withdrawn
- 2004-08-23 MX MX2010013145A patent/MX358033B/es unknown
- 2004-08-23 NZ NZ545499A patent/NZ545499A/en not_active IP Right Cessation
- 2004-08-23 CN CN2010102227346A patent/CN101919858B/zh not_active Ceased
- 2004-08-23 HU HUE15169378A patent/HUE038792T2/hu unknown
- 2004-08-23 RS RS20181262A patent/RS59969B1/sr unknown
- 2004-08-23 KR KR1020147007592A patent/KR101563222B1/ko not_active Ceased
- 2004-08-23 EP EP04816820A patent/EP1663183B9/de not_active Revoked
- 2004-08-23 ME MEP-176/08A patent/MEP17608A/xx unknown
- 2004-08-23 SI SI200432438T patent/SI2942051T1/en unknown
- 2004-08-23 CN CN200480024748XA patent/CN1901884B/zh not_active Ceased
- 2004-08-27 TW TW093125927A patent/TWI342221B/zh active
-
2006
- 2006-02-23 CR CR8256A patent/CR8256A/es unknown
- 2006-02-24 EC EC2006006397A patent/ECSP066397A/es unknown
- 2006-02-26 IL IL173939A patent/IL173939A/en active IP Right Grant
- 2006-02-27 ZA ZA200601718A patent/ZA200601718B/xx unknown
- 2006-03-24 NO NO20061342A patent/NO330282B1/no not_active Application Discontinuation
-
2007
- 2007-12-19 AU AU2007249115A patent/AU2007249115B2/en not_active Revoked
-
2008
- 2008-02-08 ZA ZA2008/01361A patent/ZA200801361B/en unknown
-
2010
- 2010-03-15 NO NO20100367A patent/NO334418B1/no not_active Application Discontinuation
- 2010-07-27 IL IL207260A patent/IL207260A/en active IP Right Grant
- 2010-11-01 AU AU2010238573A patent/AU2010238573B2/en not_active Revoked
-
2011
- 2011-02-18 JP JP2011032972A patent/JP5498411B2/ja not_active Expired - Lifetime
- 2011-07-06 JP JP2011149721A patent/JP5395125B2/ja not_active Expired - Lifetime
- 2011-09-22 CY CY20111100923T patent/CY1111981T1/el unknown
-
2012
- 2012-12-21 CR CR20120662A patent/CR20120662A/es unknown
- 2012-12-21 CR CR20120661A patent/CR20120661A/es unknown
-
2013
- 2013-02-01 CY CY20131100093T patent/CY1113596T1/el unknown
- 2013-08-13 JP JP2013168001A patent/JP5903413B2/ja not_active Expired - Lifetime
- 2013-12-27 NO NO20131743A patent/NO335326B1/no not_active Application Discontinuation
-
2015
- 2015-12-04 JP JP2015237449A patent/JP2016094433A/ja not_active Withdrawn
-
2016
- 2016-12-19 CY CY20161101315T patent/CY1118505T1/el unknown
-
2017
- 2017-09-11 JP JP2017173733A patent/JP2018035163A/ja active Pending
- 2017-09-18 IL IL254581A patent/IL254581A0/en unknown
- 2017-11-03 CY CY20171101155T patent/CY1119651T1/el unknown
-
2018
- 2018-04-17 CY CY20181100407T patent/CY1120138T1/el unknown
- 2018-12-19 HK HK18116294.9A patent/HK1257502A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516017T1 (de) | Feste pharmazeutische dosierform enthaltende ritonavir | |
| ATE297760T1 (de) | Pharmazeutische zusammensetzungen enthaltend terbinafin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1663183 Country of ref document: EP |